MicroRNA-mediated regulation of the tumor microenvironment

Cell Cycle

Volumn 12, Issue 20, 2013, Pages 3262-3271

  Chou, Jonathan ^a,b   Shahi, Payam ^a   Werb, Zena ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; LET 7A; LET 7G; MATRIX METALLOPROTEINASE; MICRORNA; MICRORNA 101; MICRORNA 125B; MICRORNA 126; MICRORNA 132; MICRORNA 148; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 17; MICRORNA 192; MICRORNA 200; MICRORNA 20B; MICRORNA 212; MICRORNA 214; MICRORNA 221; MICRORNA 29; MICRORNA 29B; MICRORNA 29C; MICRORNA 30; MICRORNA 31; MICRORNA 320; MICRORNA 335; MICRORNA 34A; MICRORNA 9; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL ADHESION; CELL HYPOXIA; CELL SURVIVAL; CYTOKINE PRODUCTION; DENDRITIC CELL; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMAN; INTRACELLULAR SIGNALING; MACROPHAGE; METASTASIS; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT;

EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; MICRORNAS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT;

EID: 84886784194     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.26087     Document Type: Article

References (120)

1. Egeblad M, Littlepage LE, Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harb Symp Quant Biol 2005; 70:383-8; PMID:16869775; http://dx.doi.org/10.1101/sqb.2005.70.007
2. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21:309-22; PMID:22439926; http://dx.doi.org/10.1016/j.ccr.2012.02.022
3. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6:17-32; PMID:15261139; http://dx.doi.org/10.1016/j.ccr.2004.06.010
4. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59:5002-11; PMID:10519415
5. Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009; 9:285-93; PMID:19308068; http://dx.doi.org/10.1038/nrc2621
6. Peinado H, Alečkoviv M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, Hergueta-Redondo M, Williams C, García-Santos G, Ghajar C, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18:883-91; PMID:22635005; http://dx.doi.org/10.1038/nm.2753
7. Psaila B, Lyden D, Roberts I. Megakaryocytes, malignancy and bone marrow vascular niches. J Thromb Haemost 2012; 10:177-88; PMID:22122829; http://dx.doi.org/10.1111/j.1538-7836.2011.04571.x
8. Qu X, Zhuang G, Yu L, Meng G, Ferrara N. Induction of Bv8 expression by granulocyte colonystimulating factor in CD11b+Gr1+ cells: key role of Stat3 signaling. J Biol Chem 2012; 287:19574-84; PMID:22528488; http://dx.doi.org/10. 1074/jbc.M111.326801
9. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, Yu L, Ross J, Korsisaari N, Cao T, et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci U S A 2010; 107:21248-55; PMID:21081700; http://dx.doi.org/10.1073/pnas. 1015855107
10. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9:654-9; PMID:17486113; http://dx.doi.org/10.1038/ncb1596
11. Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest 2013; 123:1542-55; PMID:23454749; http://dx.doi.org/10.1172/JCI66517
12. Shree T, Olson OC, Elie BT, Kester JC, Garfall AL, Simpson K, Bell-McGuinn KM, Zabor EC, Brogi E, Joyce JA. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev 2011; 25:2465-79; PMID:22156207; http://dx.doi.org/10.1101/gad.180331.111
13. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2:737-44; PMID:11025665; http://dx.doi.org/10.1038/35036374
14. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-69; PMID:16557279; http://dx.doi.org/10.1038/nrc1840
15. Lujambio A, Lowe SW. The microcosmos of cancer. Nature 2012; 482:347-55; PMID:22337054; http://dx.doi.org/10.1038/nature10888
16. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007; 8:R214; PMID:17922911; http://dx.doi.org/10.1186/gb- 2007-8-10-r214
17. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8; PMID:15944708; http://dx.doi.org/10.1038/ nature03702
18. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121:335-48; PMID:15882617; http://dx.doi.org/10.1016/j.cell.2005.02.034
19. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate iumor-promoting inflammation in an NFkappaB-dependent manner. Cancer Cell 2010; 17:135-47; PMID:20138012; http://dx.doi.org/10.1016/j.ccr.2009.12.041
20. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6:392-401; PMID:16572188; http://dx.doi.org/10.1038/nrc1877
21. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, et al. MicroRNAs reprogram normal fibroblasts into cancer associated fibroblasts in ovarian cancer. Cancer Discov 2012.
22. Long H, Xie R, Xiang T, Zhao Z, Lin S, Liang Z, Chen Z, Zhu B. Autocrine CCL5 signaling promotes invasion and migration of CD133+ ovarian cancer stemlike cells via NFκB-mediated MMP-9 upregulation. Stem Cells 2012; 30:2309-19; PMID:22887854; http://dx.doi.org/10.1002/stem.1194
23. Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, Pestell RG. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012; 72:3839-50; PMID:22637726; http://dx.doi.org/10.1158/ 0008-5472.CAN-11-3917
24. Zhang Y, Lv D, Kim HJ, Kurt RA, Bu W, Li Y, Ma X. A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res 2013; 23:394-408; PMID:23266888; http://dx.doi.org/10.1038/cr.2012.178
25. Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, Jazaeri A, et al. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle 2010; 9:4387-98; PMID:20980827; http://dx.doi.org/10.4161/cc.9.21.13674
26. Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Saccà M, Memeo L, Colarossi C, Francescangeli F, Biffoni M, Collura D, et al. Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene 2011; 30:4231-42; PMID:21532615; http://dx.doi.org/10.1038/onc.2011.140
27. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14:1271-7; PMID:18931683; http://dx.doi.org/10.1038/nm.1880
28. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, Jazaeri A, Risinger JI, et al. Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene 2013; 32:3246-53; PMID:22890324; http://dx.doi.org/10. 1038/onc.2012.351
29. Trimboli AJ, Cantemir-Stone CZ, Li F, Wallace JA, Merchant A, Creasap N, Thompson JC, Caserta E, Wang H, Chong JL, et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009; 461:1084-91; PMID:19847259; http://dx.doi.org/10.1038/nature08486
30. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, Srinivasan R, Trimboli AJ, Martin CK, Li F, et al. Reprogramming of the tumour microenvironment by stromal PTENregulated miR-320. Nat Cell Biol 2011; 14:159-67; PMID:22179046; http://dx.doi.org/10.1038/ncb2396
31. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massagué J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451:147-52; PMID:18185580; http://dx.doi.org/10. 1038/nature06487
32. Png KJ, Halberg N, Yoshida M, Tavazoie SF. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2011; 481:190-4; PMID:22170610; http://dx.doi.org/10.1038/nature10661
33. Jusufović E, Rijavec M, Keser D, Korošec P, Sodja E, Iljazović E, Radojević Z, Košnik M. let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non-small-cell lung cancer. PLoS One 2012; 7:e45577; PMID:23029111; http://dx.doi.org/10.1371/journal.pone.0045577
34. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15:272-84; PMID:18694566; http://dx.doi.org/10.1016/j.devcel.2008.07.008
35. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12:247-56; PMID:20173740
36. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, et al. A microRNA signature of hypoxia. Mol Cell Biol 2007; 27:1859-67; PMID:17194750; http://dx.doi.org/10. 1128/MCB.01395-06
37. Kulshreshtha R, Ferracin M, Negrini M, Calin GA, Davuluri RV, Ivan M. Regulation of microRNA expression: the hypoxic component. Cell Cycle 2007; 6:1426-31; PMID:17582223; http://dx.doi.org/10.4161/cc.6.12.4410
38. Cascio S, D'Andrea A, Ferla R, Surmacz E, Gulotta E, Amodeo V, Bazan V, Gebbia N, Russo A. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol 2010; 224:242-9; PMID:20232316
39. Lei Z, Li B, Yang Z, Fang H, Zhang GM, Feng ZH, Huang B. Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. PLoS One 2009; 4:e7629; PMID:19893619; http://dx.doi.org/10.1371/journal.pone.0007629
40. Nicoli S, Knyphausen CP, Zhu LJ, Lakshmanan A, Lawson ND. miR-221 is required for endothelial tip cell behaviors during vascular development. Dev Cell 2012; 22:418-29; PMID:22340502; http://dx.doi.org/10.1016/j.devcel.2012.01. 008
41. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7; PMID:12490959; http://dx.doi.org/10.1038/nature01322
42. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-99; PMID:20303878; http://dx.doi.org/10.1016/j.cell.2010.01. 025
43. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4:71-8; PMID:14708027; http://dx.doi.org/10. 1038/nrc1256
44. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9:239-52; PMID:19279573; http://dx.doi.org/10.1038/nrc2618
45. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25:315-22; PMID:16967326; http://dx.doi.org/10.1007/s10555- 006-9001-7
46. Squadrito ML, Etzrodt M, De Palma M, Pittet MJ. MicroRNA-mediated control of macrophages and its implications for cancer. Trends Immunol 2013; 34:350-9; PMID:23498847; http://dx.doi.org/10.1016/j.it.2013.02.003
47. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A 2007; 104:1604-9; PMID:17242365; http://dx.doi.org/10.1073/pnas.0610731104
48. Martinez-Nunez RT, Louafi F, Sanchez-Elsner T. The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). J Biol Chem 2011; 286:1786-94; PMID:21097505; http://dx.doi.org/10.1074/jbc.M110.169367
49. Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest 2012; 122:4190-202; PMID:23041630; http://dx.doi.org/10.1172/JCI61716
50. Chaudhuri AA, So AY, Sinha N, Gibson WS, Taganov KD, O'Connell RM, Baltimore D. MicroRNA-125b potentiates macrophage activation. J Immunol 2011; 187:5062-8; PMID:22003200; http://dx.doi.org/10.4049/jimmunol.1102001
51. Yang M, Chen J, Su F, Yu B, Su F, Lin L, Liu Y, Huang JD, Song E. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer 2011; 10:117; PMID:21939504; http://dx.doi.org/10.1186/1476-4598-10-117
52. Bezman NA, Chakraborty T, Bender T, Lanier LL. miR-150 regulates the development of NK and iNKT cells. J Exp Med 2011; 208:2717-31; PMID:22124110; http://dx.doi.org/10.1084/jem.20111386
53. Trotta R, Chen L, Ciarlariello D, Josyula S, Mao C, Costinean S, Yu L, Butchar JP, Tridandapani S, Croce CM, et al. miR-155 regulates IFN-γ production in natural killer cells. Blood 2012; 119:3478-85; PMID:22378844; http://dx.doi.org/10.1182/blood-2011-12-398099
54. Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B, Bi C, Tan J, Kwong YL, Shimizu N, et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood 2011; 118:4919-29; PMID:21921041; http://dx.doi.org/10.1182/blood-2011-07-364224
55. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol 2013; 15:284-94; PMID:23396050; http://dx.doi.org/10. 1038/ncb2690
56. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, Coussens LM. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16:91-102; PMID:19647220; http://dx.doi.org/10.1016/j.ccr.2009.06.018
57. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470:548-53; PMID:21326202; http://dx.doi.org/10.1038/nature09707
58. Wu ZS, Wang CQ, Xiang R, Liu X, Ye S, Yang XQ, Zhang GH, Xu XC, Zhu T, Wu Q. Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer 2012; 12:51; PMID:22292984; http://dx.doi.org/10.1186/1471- 2407-12-51
59. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447:1130-4; PMID:17554337; http://dx.doi.org/10.1038/ nature05939
60. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141:52-67; PMID:20371345; http://dx.doi.org/10.1016/j.cell.2010.03.015
61. Xu N, Zhang L, Meisgen F, Harada M, Heilborn J, Homey B, Grandér D, Ståhle M, Sonkoly E, Pivarcsi A. MicroRNA-125b down-regulates matrix metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma cell proliferation, migration, and invasion. J Biol Chem 2012; 287:29899-908; PMID:22782903; http://dx.doi.org/10.1074/jbc.M112.391243
62. Zhang H, Qi M, Li S, Qi T, Mei H, Huang K, Zheng L, Tong Q. microRNA-9 targets matrix metalloproteinase 14 to inhibit invasion, metastasis, and angiogenesis of neuroblastoma cells. Mol Cancer Ther 2012; 11:1454-66; PMID:22564723; http://dx.doi.org/10.1158/1535-7163.MCT-12-0001
63. Ucar A, Vafaizadeh V, Jarry H, Fiedler J, Klemmt PA, Thum T, Groner B, Chowdhury K. miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. Nat Genet 2010; 42:1101-8; PMID:21057503; http://dx.doi.org/10.1038/ng.709
64. Formosa A, Lena AM, Markert EK, Cortelli S, Miano R, Mauriello A, Croce N, Vandesompele J, Mestdagh P, Finazzi-Agrò E, et al. DNA methylation silences miR-132 in prostate cancer. Oncogene 2013; 32:127-34; PMID:22310291; http://dx.doi.org/10.1038/onc.2012.14
65. Li S, Meng H, Zhou F, Zhai L, Zhang L, Gu F, Fan Y, Lang R, Fu L, Gu L, et al. MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. Pathol Res Pract 2013; 209:179-83; PMID:23399321; http://dx.doi.org/10.1016/j.prp.2012.12.002
66. Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J, Zhou J, Wu J, Shao C. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis 2011; 32:1183-9; PMID:21665894; http://dx.doi.org/10.1093/carcin/bgr105
67. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res 2011; 13:223; PMID:22114898; http://dx.doi.org/10.1186/bcr2942
68. Lyons TR, O'Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, Marusyk A, Tan AC, Schedin P. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med 2011; 17:1109-15; PMID:21822285; http://dx.doi.org/10.1038/nm.2416
69. Nguyen-Ngoc KV, Cheung KJ, Brenot A, Shamir ER, Gray RS, Hines WC, Yaswen P, Werb Z, Ewald AJ. ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium. Proc Natl Acad Sci U S A 2012; 109:E2595-604; PMID:22923691; http://dx.doi.org/10.1073/pnas. 1212834109
70. Ji J, Zhao L, Budhu A, Forgues M, Jia HL, Qin LX, Ye QH, Yu J, Shi X, Tang ZY, et al. Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol 2010; 52:690-7; PMID:20338660; http://dx.doi.org/10.1016/j.jhep.2009.12.025
71. Makino K, Jinnin M, Hirano A, Yamane K, Eto M, Kusano T, Honda N, Kajihara I, Makino T, Sakai K, et al. The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. J Immunol 2013; 190:3905-15; PMID:23509348; http://dx.doi.org/10.4049/jimmunol.1200822
72. Dangi-Garimella S, Strouch MJ, Grippo PJ, Bentrem DJ, Munshi HG. Collagen regulation of let-7 in pancreatic cancer involves TGF-β1-mediated membrane type 1-matrix metalloproteinase expression. Oncogene 2011; 30:1002-8; PMID:21057545; http://dx.doi.org/10.1038/onc.2010.485
73. Erler JT, Bennewith KL, Nicolau M, Dornhöfer N, Kong C, Le QT, Chi JT, Jeffrey SS, Giaccia AJ. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006; 440:1222-6; PMID:16642001; http://dx.doi.org/10.1038/ nature04695
74. Barker HE, Chang J, Cox TR, Lang G, Bird D, Nicolau M, Evans HR, Gartland A, Erler JT. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res 2011; 71:1561-72; PMID:21233336; http://dx.doi.org/10. 1158/0008-5472.CAN-10-2868
75. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 2010; 16:1009-17; PMID:20818376; http://dx.doi.org/10.1038/nm.2208
76. Moreno-Bueno G, Salvador F, Martín A, Floristán A, Cuevas EP, Santos V, Montes A, Morales S, Castilla MA, Rojo-Sebastián A, et al. Lysyl oxidaselike 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol Med 2011; 3:528-44; PMID:21732535; http://dx.doi.org/10.1002/emmm.201100156
77. Sengupta S, den Boon JA, Chen IH, Newton MA, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B, Ahlquist P. MicroRNA 29c is downregulated in nasopharyngeal carcinomas, upregulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci U S A 2008; 105:5874-8; PMID:18390668; http://dx.doi.org/10.1073/pnas.0801130105
78. Shan SW, Lee DY, Deng Z, Shatseva T, Jeyapalan Z, Du WW, Zhang Y, Xuan JW, Yee SP, Siragam V, et al. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression. Nat Cell Biol 2009; 11:1031-8; PMID:19633662; http://dx.doi.org/10.1038/ncb1917
79. Zhang X, Ladd A, Dragoescu E, Budd WT, Ware JL, Zehner ZE. MicroRNA-17-3p is a prostate tumor suppressor in vitro and in vivo, and is decreased in high grade prostate tumors analyzed by laser capture microdissection. Clin Exp Metastasis 2009; 26:965-79; PMID:19771525; http://dx.doi.org/10.1007/s10585-009- 9287-2
80. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, McCue PA, Quong AA, Lisanti MP, Pestell RG. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A 2010; 107:8231-6; PMID:20406904; http://dx.doi.org/10.1073/pnas.1002080107
81. Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massagué J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011; 17:867-74; PMID:21706029; http://dx.doi.org/10.1038/nm.2379
82. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137:1032-46; PMID:19524507; http://dx.doi.org/10.1016/j.cell.2009.03.047
83. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 2010; 70:5147-54; PMID:20530680; http://dx.doi.org/10.1158/0008-5472.CAN-10-0410
84. Wang G, Mao W, Zheng S. MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett 2008; 582:3663-8; PMID:18840437; http://dx.doi.org/10. 1016/j.febslet.2008.09.051
85. Li G, Luna C, Qiu J, Epstein DL, Gonzalez P. Targeting of integrin beta1 and kinesin 2alpha by microRNA 183. J Biol Chem 2010; 285:5461-71; PMID:19940135; http://dx.doi.org/10.1074/jbc.M109.037127
86. Hunt S, Jones AV, Hinsley EE, Whawell SA, Lambert DW. MicroRNA-124 suppresses oral squamous cell carcinoma motility by targeting ITGB1. FEBS Lett 2011; 585:187-92; PMID:21112327; http://dx.doi.org/10.1016/j.febslet.2010.11.038
87. Yu F, Deng H, Yao H, Liu Q, Su F, Song E. Mir-30 reduction maintains self-renewal and inhibits apoptosis in breast tumor-initiating cells. Oncogene 2010; 29:4194-204; PMID:20498642; http://dx.doi.org/10.1038/onc.2010.167
88. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ, Ang LC, He C, Shan SW, et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-β8. Oncogene 2011; 30:806-21; PMID:20956944; http://dx.doi.org/10.1038/onc.2010.465
89. Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber ER, McDonald HA, Potter DM, Hamilton RL, Lotze MT, et al. Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A 2009; 106:10746-51; PMID:19520829; http://dx.doi.org/10.1073/pnas.0811817106
90. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol 2013; 15:201-13; PMID:23354167; http://dx.doi.org/10. 1038/ncb2672
91. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, et al. NFkappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 2008; 14:369-81; PMID:18977326; http://dx.doi.org/10.1016/j.ccr.2008.10.006
92. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 2007; 104:15805-10; PMID:17890317; http://dx.doi.org/10.1073/pnas.0707628104
93. Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL, Hoon DS. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 2011; 6:388-94; PMID:21081840; http://dx.doi.org/10.4161/epi.6.3.14056
94. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51:836-45; PMID:20041405
95. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26:6133-40; PMID:17404574; http://dx.doi.org/10.1038/sj.onc.1210436
96. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, et al. MicroRNA 29b functions in acute myeloid leukemia. Blood 2009; 114:5331-41; PMID:19850741; http://dx.doi.org/10. 1182/blood-2009-03-211938
97. Zhu C, Wang Y, Kuai W, Sun X, Chen H, Hong Z. Prognostic value of miR-29a expression in pediatric acute myeloid leukemia. Clin Biochem 2013; 46:49-53; PMID:22981932; http://dx.doi.org/10.1016/j.clinbiochem.2012.09.002
98. Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, Zhang JP, Guan XY, Zhuang SM. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 2011; 54:1729-40; PMID:21793034; http://dx.doi.org/10.1002/hep.24577
99. Li P, Guo W, Du L, Zhao J, Wang Y, Liu L, Hu Y, Hou Y. microRNA-29b contributes to pre-eclampsia through its effects on apoptosis, invasion and angiogenesis of trophoblast cells. Clin Sci (Lond) 2013; 124:27-40; PMID:22716646; http://dx.doi.org/10.1042/CS20120121
100. Suh EJ, Remillard MY, Legesse-Miller A, Johnson EL, Lemons JM, Chapman TR, Forman JJ, Kojima M, Silberman ES, Coller HA. A microRNA network regulates proliferative timing and extracellular matrix synthesis during cellular quiescence in fibroblasts. Genome Biol 2012; 13:R121; PMID:23259597; http://dx.doi.org/10.1186/gb-2012-13-12-r121
101. Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian JB. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J Biol Chem 2009; 284:15676-84; PMID:19342382; http://dx.doi.org/10.1074/jbc.M809787200
102. Liu Y, Taylor NE, Lu L, Usa K, Cowley AW Jr., Ferreri NR, Yeo NC, Liang M. Renal medullary microRNAs in Dahl salt-sensitive rats: miR-29b regulates several collagens and related genes. Hypertension 2010; 55:974-82; PMID:20194304; http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.144428
103. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 2008; 105:13027-32; PMID:18723672; http://dx.doi.org/10.1073/pnas.0805038105
104. Maurer B, Stanczyk J, Jüngel A, Akhmetshina A, Trenkmann M, Brock M, Kowal-Bielecka O, Gay RE, Michel BA, Distler JH, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum 2010; 62:1733-43; PMID:20201077; http://dx.doi.org/10.1002/art.27443
105. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One 2011; 6:e16915; PMID:21364938; http://dx.doi.org/10.1371/journal.pone.0016915
106. Schedin P, Keely PJ. Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb Perspect Biol 2011; 3:a003228; PMID:20980442; http://dx.doi.org/10.1101/ cshperspect.a003228
107. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT, Giaccia AJ. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15:35-44; PMID:19111879; http://dx.doi.org/10.1016/j.ccr.2008.11.012
108. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer 2009; 9:108-22; PMID:19165226; http://dx.doi.org/10. 1038/nrc2544
109. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139:891-906; PMID:19931152; http://dx.doi.org/10.1016/j.cell.2009.10.027
110. Mannaerts I, Eysackers N, Onyema OO, Van Beneden K, Valente S, Mai A, Odenthal M, van Grunsven LA. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. PLoS One 2013; 8:e55786; PMID:23383282; http://dx.doi.org/10.1371/journal.pone.0055786
111. Steele R, Mott JL, Ray RB. MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrixmetalloproteinase-2 in prostate cancer cells. Genes Cancer 2010; 1:381-7; PMID:20657750; http://dx.doi.org/10.1177/1947601910371978
112. Ding Q, Chang CJ, Xie X, Xia W, Yang JY, Wang SC, Wang Y, Xia J, Chen L, Cai C, et al. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest 2011; 121:4526-36; PMID:21985787; http://dx.doi.org/10.1172/JCI45008
113. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. Generation of a functional mammary gland from a single stem cell. Nature 2006; 439:84-8; PMID:16397499; http://dx.doi.org/10.1038/nature04372
114. Lo PK, Kanojia D, Liu X, Singh UP, Berger FG, Wang Q, Chen H. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling. Oncogene 2012; 31:2614-26; PMID:21996747; http://dx.doi.org/10.1038/onc.2011.439
115. Yu KR, Yang SR, Jung JW, Kim H, Ko K, Han DW, Park SB, Choi SW, Kang SK, Schöler H, et al. CD49f enhances multipotency and maintains stemness through the direct regulation of OCT4 and SOX2. Stem Cells 2012; 30:876-87; PMID:22311737; http://dx.doi.org/10.1002/stem.1052
116. Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene 2013; 32:2555-64; PMID:22751119; http://dx.doi.org/10.1038/onc.2012.275
117. Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol 2010; 222:42-9; PMID:19798694; http://dx.doi.org/10.1002/jcp.21943
118. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 2006; 127:1041-55; PMID:17129787; http://dx.doi.org/10.1016/j.cell.2006.09.048
119. Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008; 13:141-52; PMID:18242514; http://dx.doi.org/10.1016/j.ccr.2008.01.011
120. Du Y, Gao C, Liu Z, Wang L, Liu B, He F, Zhang T, Wang Y, Wang X, Xu M, et al. Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification. Arterioscler Thromb Vasc Biol 2012; 32:2580-8; PMID:22995515; http://dx.doi.org/10.1161/ATVBAHA.112.300206